Compare Immunovant Inc. Common Stock (IMVT) vs MetLife Inc. Common Stock (MET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs MetLife Inc. Common Stock — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while MetLife Inc. Common Stock trades at $98.97 (market cap $60.87B). The key difference: MetLife Inc. Common Stock is far larger — about 9.2× Immunovant Inc. Common Stock's market cap, and MetLife Inc. Common Stock pays a 2.47% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and MetLife Inc. Common Stock for 0 Days on average.
| IMVT | MET | |
|---|---|---|
Market Cap | $6.62B | $60.87B |
Volume | 1,131,364 | 3,175,937 |
Sector | Health | Financials |
52-Week High | $44.96 | $99.95 |
52-Week Low | $17.03 | $67.70 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.72B | $81.79B |
Dividend Yield | — | 2.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About MetLife Inc. Common Stock
MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.
Read more on MET →
